eligibility_summary
Eligible: adults 18–75 with histologically confirmed colorectal adenocarcinoma, synchronous liver-only metastases deemed initially unresectable by MDT, life expectancy >6 mo, RAS/BRAF V600E wild-type, ECOG 0–1, baseline CT. Exclude: prior systemic/surgical therapy for metastases, extrahepatic disease, unresectable primary, major CV event ≤12 mo, bowel obstruction, another cancer ≤5 yrs, substance abuse, legal incapacity, uncontrolled HTN (≥3 drugs).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05873972 tests AI-guided versus clinician-selected biologic choice with chemotherapy in unresectable, liver-only, RAS/BRAF WT colorectal cancer. Drugs/interventions: (1) Cetuximab + FOLFOX or (2) Bevacizumab + FOLFOX, with selection by a multimodal deep-learning signature (CT imaging + mutation data) or by clinician judgment. Mechanisms and types: Cetuximab—chimeric IgG1 anti-EGFR mAb, blocks EGFR, inhibiting RAS-RAF-MEK-ERK and PI3K-AKT signaling, can trigger ADCC via NK cells. Bevacizumab—humanized anti-VEGF-A mAb, antiangiogenic via VEGF/VEGFR blockade on endothelial cells. FOLFOX: 5-FU (TS inhibitor) + leucovorin (enhancer) + oxaliplatin (DNA crosslinker), targeting rapidly dividing tumor cells. Targets: tumor EGFR pathways, tumor proliferation/DNA synthesis, tumor vasculature via VEGF.